Moleac partners with Ferron Par in Indonesia for NeuroAiD II

On October 21, 2024, significant changes are occurring in the pharmaceutical landscape in Indonesia with Moleac announcing a new partnership. Effective January 1, 2025, PT Ferron Par Pharmaceuticals will take over as the exclusive partner for NeuroAiD II MLC901. This transition marks a critical shift following a successful 12-year collaboration with PT Mersifarma Tirmaku Mercusana, whose contributions have been integral to Moleac's success in the Indonesian market. Ferron, a notable player in the market and a member of the Dexa Group, has established itself among the top 20 pharmaceutical companies in Indonesia. With an extensive product range and advanced manufacturing capabilities, Ferron is well-positioned to enhance market presence and operational excellence. The company aims to leverage this partnership to further its commitment to health and independence in Indonesia, aligning with Moleac's broader mission. Moleac’s decision to transition partners suggests a strategic shift aimed at strengthening its operations and enhancing product availability in Indonesia. The pharmaceutical company is optimistic about what this new partnership will bring and is thankful for the fruitful history it has had with its previous partner. The end of this long-standing collaboration underlines the dynamic nature of the pharmaceutical industry within the region. The announcement reflects a broader trend in the pharmaceutical sector, where partnerships and collaborations are vital for market expansion and competitive advantage. As Moleac embarks on this new chapter, industry observers will be keenly watching how the partnership with Ferron unfolds in the coming years.